Preclinical Manufacturing Viral Vaccines

Our capabilities and experience qualify us to be your research partner and deliver your viral vaccines.

Your research is only valuable if your data can be reproduced. It is therefore crucial that high quality, well-characterized research materials for your preclinical studies are used.

We are very experienced in growing wildtype and attenuated viruses on mammalian cell lines in adherent, microcarrier-based, or suspension cell culture. Hereto, we have a variety of cell lines at our disposal, such as modified, cloned, or parental Vero, MRC-5, and MDCK cell lines. Using these platforms, we manufacture a wide range of viruses including polio, measles, rubella, influenza and rotavirus.

Manufacturing equipment

We can utilize a range of different manufacturing scales for preclinical manufacturing ranging from high-throughput 20 mL spin tubes up to 200 L bioreactors. The equipment ranges from shake flasks and cell factories to WAVE Bioreactors™, and fixed-bed bioreactors, such as the iCELLis® and scale-X™. Subsequently, the different upstream scales are matched with appropriately scaled downstream equipment for clarification, concentration, chromatography and filtration.

For the purification of viruses, we offer clarification by depth filtration with a variety of different filters. This includes filters combining particle purification and impurity removal. Removal of nucleic acids is often required for viral products. The removal can be achieved by techniques, such as enzymatic digestion or fractional precipitation. Prior to purification, concentration and buffer exchange using tangential flow filtration can be performed using hollow fibers or flat screens. This is dependent on the physical properties of the target virus and the requirements of the final product.

Purification is normally achieved using several chromatography steps. The type of chromatography used is dependent on the virus properties. Commonly for purification, ion-exchange or hydrophobic interaction differences are exploited. For polishing and formulation, size-based group separation or tangential flow filtration can be used. Depending on the size of the viral product, a sterile filtration can be performed, while for larger viruses, for which this approach is not feasible, an aseptic manufacturing process can be performed. For analysis of the product, we offer a variety of product specific assays and assay development services, such as TCID50, PFA, FFA, ELISA, (q)PCR and HPLC-based methods.

Preclinical manufacturing track record

Our broad experience with viral vaccine production, process development, and assays allows us to deliver a complete package. You receive purified vaccine with the associated biochemical and analytical characterization data. We have successfully delivered various vaccines for preclinical studies, such as hepatitis A, influenza, Sabin polio, Salk polio and RSV.

Process development
Clinical manufacturing
Knowledge center

Talk to our experts

Angelique Lemckert - bioprocess expert
Angelique Lemckert

Technical Lead
+31 (0) 88 9950600

Send us a message